Background
==========

The Delphian lymph node (DLN) is the highest of the central (level 6) cervical lymph nodes. The classic DLN is ascribed to one or more lymph nodes above the isthmus of the thyroid gland between the cricoid and thyroid cartilage, although it also includes any midline node placed over the cricothyroid membrane, cricoid cartilage, or that lies anterior to the lower half of the thyroid cartilage \[[@b1-poljradiol-81-72],[@b2-poljradiol-81-72]\].

Many reports show the involvement of the DLN in head-neck malignancies. These reports suggest that these lymph nodes are important during surgery and for the prognosis of thyroid, laryngeal, and glottis tumours \[[@b3-poljradiol-81-72]--[@b6-poljradiol-81-72]\].

Involvement of the DLN in autoimmune thyroiditis (AT) has gained wide acceptance, although it has been mentioned only superficially in some reference books \[[@b7-poljradiol-81-72],[@b8-poljradiol-81-72]\]. Despite this common knowledge, an insufficient number of studies have demonstrated an association between AT and the DLN. Some studies discuss the coexistence of subacute thyroiditis and the central cervical lymph node \[[@b9-poljradiol-81-72]\] and the coexistence of various AT stages and cervical lymph nodes \[[@b10-poljradiol-81-72]\]. However, that study did not include indeterminate cases, which may be an early phase of AT, as discussed in our study.

The diagnosis of AT is based on clinical findings and laboratory tests, such as elevated thyroglobulin antibody (Tg Ab) and thyroid peroxidase antibody (TPO Ab). However, anti-thyroid antibodies can be negative in cases of thyroiditis, as evidenced by a histological examination \[[@b11-poljradiol-81-72]\]. Some authors advocate use of ultrasonography (US) in cases of AT \[[@b12-poljradiol-81-72],[@b13-poljradiol-81-72]\], whereas it was found to be useless by other authors \[[@b14-poljradiol-81-72]\]. The combination of US with clinical and serological assessments significantly improves sensitivity and specificity for diagnosing AT \[[@b15-poljradiol-81-72],[@b16-poljradiol-81-72]\]. In addition, sonography is a non-invasive modality that provides information about the level of inflammatory activity \[[@b17-poljradiol-81-72]\] and the severity of thyroiditis \[[@b18-poljradiol-81-72]\].

The sonographic characteristics of AT are well defined and used during routine US examinations. However, some cases of early thyroiditis present with very superficial and subtle sonographic findings, making it extremely difficult to confirm the thyroiditis diagnosis in these early cases by looking only at the US characteristics of the gland.

This study evaluated the association between autoimmune thyroiditis and the Delphian lymph node during different stages of thyroiditis.

Material and Methods
====================

This study was approved by the university Ethics Committee. This study was conducted with 126 cases (90 females and 36 males) between June 2012 and February 2014. Among the patients referred for US evaluation, pregnant and breastfeeding women, paediatric cases and patients who had undergone surgery, and those with a known malignancy, short neck, marked goitre, thyroid nodules, and cases with a recent history of viral or bacterial infection were excluded.

All patients underwent physical and US evaluations and laboratory tests. The cases were evaluated by a single radiologist who was blinded to the laboratory data.

The laboratory tests included free triiodothyronine (fT3), free thyroxine (fT4), thyroid-stimulating hormone (TSH), TPO Ab, and Tg Ab levels.

The histopathological findings and sonographic features in different stages of autoimmune thyroiditis have been reported and are used routinely in clinical practice \[[@b13-poljradiol-81-72],[@b15-poljradiol-81-72]--[@b17-poljradiol-81-72],[@b19-poljradiol-81-72]--[@b30-poljradiol-81-72]\] ([Table 1](#t1-poljradiol-81-72){ref-type="table"}). Diffuse enlargement, parenchymal hypoechogenicity and coarsening \[[@b13-poljradiol-81-72],[@b16-poljradiol-81-72],[@b19-poljradiol-81-72],[@b21-poljradiol-81-72],[@b25-poljradiol-81-72],[@b30-poljradiol-81-72]\], diffuse reduction of echogenicity (compared to the surrounding muscles) \[[@b13-poljradiol-81-72],[@b16-poljradiol-81-72],[@b21-poljradiol-81-72],[@b25-poljradiol-81-72],[@b30-poljradiol-81-72]\], echogenic interlobular septation on the heterogeneous hypoechoic basement, and a diffuse micronodular pattern \[[@b13-poljradiol-81-72],[@b16-poljradiol-81-72],[@b19-poljradiol-81-72],[@b21-poljradiol-81-72],[@b25-poljradiol-81-72],[@b30-poljradiol-81-72]\] have been observed in patients with thyroiditis. Thyroid gland vascularity increases with the stage of thyroiditis \[[@b13-poljradiol-81-72],[@b16-poljradiol-81-72],[@b20-poljradiol-81-72],[@b21-poljradiol-81-72],[@b25-poljradiol-81-72],[@b30-poljradiol-81-72]\]. As the disease advances, the septa increase in extent and become more echogenic, parenchymal heterogeneity increases, and contour lobulation deepens. Pseudonodulation and gland shrinkage are also observed ([Table 1](#t1-poljradiol-81-72){ref-type="table"}).

According to Gutekunst et al., 5.4% of Hashimoto's thyroiditis cases have normal US findings \[[@b15-poljradiol-81-72]\]. Langer et al. reported that the variety in the sonographic features of AT match the phase and severity of the disease \[[@b24-poljradiol-81-72]\]. In a study of 2,267 cases, Kim et al. study evaluated different diffuse thyroid diseases, including Hashimoto's thyroiditis, using echogenicity (iso-, hypo-, marked hypo-, hyperechoic), echo texture (fine, coarse, micronodular), dimensions and contour properties (smooth, macrolobular, microlobular) of the gland \[[@b26-poljradiol-81-72]\]. Willms et al. argued that it is possible to diagnose Hashimoto's thyroiditis from the sonographic findings and that these findings can be used to follow the disease. They developed the VESINC system (volume, echogenicity, sonographic texture, pseudo-nodular hypoechoic infiltration, nodule presence, and cyst presence) to classify different sonographic properties of the gland \[[@b17-poljradiol-81-72]\]. Except for nodule and cyst presence, the parameters of the other sonographic criteria were the same as those used in our study. We did not include cases with nodules since we did not evaluate the histopathology.

Our study used the sonographic criteria defined in the literature for Hashimoto's thyroiditis ([Table 1](#t1-poljradiol-81-72){ref-type="table"}), including those of Kim et al., Gutekunst et al., and Willms et al., to define the sonographic criteria of our cases to clarify the histopathological progression of the disease and its sonographic consequences \[[@b15-poljradiol-81-72],[@b17-poljradiol-81-72],[@b26-poljradiol-81-72]\].

Size, contour (regular or irregular), echo texture (homogeneous or heterogeneous), echogenicity (hypoechoic or hyperechoic), presence of nodules or pseudo-nodules, thyroid gland vascularity (decreased, normal, or increased), and the DLN (long- and short-axis diameters; long-axis/short-axis ratios; absence or presence of the hilum) were evaluated by Doppler sonography (LOGIQ P6 Pro, GE Healthcare, Mannheim, Germany) with a linear 11 MHz probe, with the patients in a supine position with neck hyperextension.

The patients were divided into four groups according to the US findings, which are defined above: 1-control cases, 2-indeterminate cases, 3-established thyroiditis cases, and 4-advanced-late stage thyroiditis cases. Group 1 (control cases) consisted of cases with normal US, clinical, and laboratory findings ([Figure 1](#f1-poljradiol-81-72){ref-type="fig"}). Group 2 (indeterminate cases) comprised cases that were decided based on detecting early thyroiditis on a sonographic examination ([Figure 2](#f2-poljradiol-81-72){ref-type="fig"}). Group 3 (established thyroiditis cases) consisted of cases with decreased parenchymal echogenicity, nonhomogeneous echo texture, and echogenic interlobular septa ([Figure 3](#f3-poljradiol-81-72){ref-type="fig"}). Group 4 (advanced-late stage thyroiditis cases) was composed of cases with a more hypoechoic parenchyma and a marked nonhomogeneous echo texture, irregular contour, pseudo-nodules, and reduced size ([Figure 4](#f4-poljradiol-81-72){ref-type="fig"}).

Groups 3 and 4 were combined to make a definite thyroiditis group to compare between the control cases and AT cases. Clinical, laboratory, and radiological 1-year follow-ups were performed to clarify the indeterminate cases. At the beginning of the study, 49 cases were considered indeterminate based on sonographic characteristics. These cases were followed up; however, seven patients did not attend the 1-year follow-up visit. Among 42 cases, 33 with confirmed thyroiditis at the sonographic follow-up were included in the study as Group 2.

Electrochemiluminescence immunoassay kits were used to measure the fT3, fT4, TSH, Tg Ab, and TPO Ab levels.

Statistical analyses were performed using Number Cruncher Statistical System 2007 & PASS 2008 Statistical Software (Kaysville, UT, USA). In addition to descriptive statistics (mean, standard deviation, median, frequency, ratio, and range), one-way analysis of variance was used to compare three or more groups with normally distributed data. Tukey's HSD test was used to identify differences. The Kruskal--Wallis test was used to compare three or more groups with data that were not normally distributed, and the Mann-Whitney *U*-test was used to detect differences. Pearson's chi-square test, Fisher's exact test, Fisher-Freeman-Halton test, and Yates Continuity Correction test (chi-square with Yates correction) were used to compare qualitative data. Spearman's correlation analysis was used to evaluate the relationship between parameters. A p\<0.05 was considered significant.

Results
=======

Study group characteristics
---------------------------

The mean age of the study subjects was 38.21±12.51 years (range, 18--73 years) ([Table 2](#t2-poljradiol-81-72){ref-type="table"}).

Of the patients, 71.4% were female (n=90) and 28.6% were male (n=36). Of the cases, 24% (n=30) were control cases (Group 1), 26% (n=33) were indeterminate cases (Group 2), 19% (n=24) were established thyroiditis cases (Group 3), and 30% (n=39) were advanced-late stage cases (Group 4).

Characteristics of the thyroid gland and Delphian lymph nodes
-------------------------------------------------------------

A significant difference was observed between the DLN detection rates of the groups (Pearson's chi-square test, p=0.001) ([Table 3](#t3-poljradiol-81-72){ref-type="table"}).

The Delphian lymph node was found significantly more frequently in Group 4 than in Groups 1 and 2 (p\<0.01) and significantly more frequently in Group 3 than in Group 1 (p\<0.05). Although there was a difference between Groups 2 and 3, it was not significant. There was no significant difference between Groups 1 and 2 (p\>0.05).

Both the long and short axis measurements were significantly higher in Groups 2, 3, and 4 than those in the control group (Mann-Whitney *U*-test; long axis: p=0.035, 0.028, and 0.007, respectively; short axis: 0.025, 0.014, and 0.006, respectively). However, the same increase was not observed in the long/short axis ratio of the DLN ([Table 4](#t4-poljradiol-81-72){ref-type="table"}).

The mean diameter of the long axis in the definite thyroiditis group (Groups 3 and 4) was 6.5±1.8 mm. The mean diameter of the short axis was 2.7±0.7 mm, and the mean ratio of the long-to-short-axis was 2.3±0.4. The diameter of the long axis was 2.2-fold higher and the diameter of the short axis was 1.9-fold higher in patients diagnosed with definite thyroiditis when the average DLN diameter was considered, compared with those in the control group.

The DLN detection rate was extremely low in the control group (10%), as expected; thus, the cut-off value, sensitivity, and specificity could not be calculated.

An assessment of the hilum could not be performed due to the small size of the DLN. A significant difference in vascularisation of the parenchyma was observed between groups 1 and 4 (Yates' Continuity Correction Test, p=0.049). A trend for increased vascularity of the thyroid gland was observed from control patients toward cases with definite thyroiditis (established \[Group 3\] and advanced-late thyroiditis \[group 4\]) (6.7%, 12.1%, 29.2%, and 28.2%, respectively) ([Table 3](#t3-poljradiol-81-72){ref-type="table"}).

No significant differences in Tg Ab or TPO Ab levels were observed between the indeterminate and control cases ([Table 2](#t2-poljradiol-81-72){ref-type="table"}). Patients with DLN had significantly higher Tg Ab and TPO Ab levels than the patients without DLN (p=0.001, Mann-Whitney *U-*test).

A positive correlation was observed between the long and short axis of the DLN and TPO Ab level (TPO Ab increased with increasing DLN long axis and short axis measurements) (long axis: r=0.521; p=0.001; short axis: r=0.429; p=0.001) ([Table 5](#t5-poljradiol-81-72){ref-type="table"}). No association was observed between the long axis/short axis ratio of the DLN and TPO Ab level ([Table 5](#t5-poljradiol-81-72){ref-type="table"}).

Tg Ab and TPO Ab levels in cases with increased vascularity were significantly higher than those with normal vascularity (p=0.013 and p=0.002, respectively, Mann-Whitney *U-*test) ([Table 5](#t5-poljradiol-81-72){ref-type="table"}).

Discussion
==========

Autoimmune thyroiditis develops as a result of lymphocytic infiltration into the thyroid gland. This infiltration destroys the parenchyma, resulting in decreased US echogenicity \[[@b28-poljradiol-81-72]\]. Several studies have indicated that US predicts parenchymal inflammation and destruction of the thyroid gland \[[@b31-poljradiol-81-72]\]. Rago et al. suggested that use of US in the early stages may help predict future development of thyroid dysfunction more readily than using thyroid autoantibodies \[[@b32-poljradiol-81-72]\]. However, it could be difficult to assess decreased echogenicity and coarsening or micronodulation of the echotexture in early cases of suspected AT (our early stage or indeterminate cases) and eventually reach a conclusion on involvement of the thyroid gland only by looking at the sonographic data.

A radiologist would like to refer to other thyroid gland characteristics, such as vascularity and serum thyroid antibodies. Gutekunst et al. argued that it is possible for experienced radiologists to diagnose AT using high-resolution sonographic equipment despite the fact that the thyroid structures might be seen as normal \[[@b15-poljradiol-81-72]\].

According to our data, DLN dimensions increase during the early stage of thyroiditis but vascularity and serum antibodies did not increase during this indeterminate phase. The Tg Ab and TPO Ab levels were elevated significantly when prominent thyroid gland heterogeneity and increased vascularisation were detected ([Table 5](#t5-poljradiol-81-72){ref-type="table"}). Therefore, evaluating the DLN becomes important during the early (indeterminate) stage ([Figure 2](#f2-poljradiol-81-72){ref-type="fig"}).

Sonography can give information about the level of inflammatory activity \[[@b17-poljradiol-81-72]\] and thyroiditis severity \[[@b18-poljradiol-81-72]\]. As thyroiditis progresses, evaluating the gland with DLN provides more information about the different stages of AT. In the present study, the DLN was detected in only three of 30 control patients (10%). The DLN detection rates were 15.1% for indeterminate cases, 41.6% for established thyroiditis cases, and 56.4% for advanced-late stage thyroiditis cases. According to the current data, the DLN detection rate increases as thyroiditis becomes more established. Giovagnorio et al. also observed an increase in the rate of DLN detection with advancing thyroiditis stage \[[@b10-poljradiol-81-72]\]. In their study, no significant difference in lymph node size was found among the groups; however, the presence and number of DLNs differed significantly across groups \[[@b10-poljradiol-81-72]\]. We found significant differences in the presence of the DLN, which became more significant with advancing thyroiditis stage ([Tables 3](#t3-poljradiol-81-72){ref-type="table"}, [4](#t4-poljradiol-81-72){ref-type="table"}). By contrast, we found that long and short axis measurements were significantly higher in Groups 2, 3, and 4 compared to those in the control group. No significant difference in DLN size was observed between the indeterminate and definite thyroiditis (Groups 3 and 4) cases. Therefore, measuring the DLN dimensions might aid in the diagnosis of early AT.

Some studies have reported a minimal axial diameter of 8 mm for reactive lymph nodes, except for the subdigastric and submandibular nodes \[[@b33-poljradiol-81-72]\]; however, there is no commonly accepted lymph node size associated with AT.

The mean values for the long axis and short axis in Groups 3 and 4 (definite thyroiditis) were 6.5±1.8 and 2.7±0.7 mm, respectively. As the DLN detection rate was extremely low in the control group (10%), as expected, the cut-off value, sensitivity, and specificity could not be calculated. This is a limitation of this study. We suggest a cut-off value for the DLN (long axis: 3.95; short axis: 1.55), although these values are not significant.

Giovagnorio et al. reported a mean long-axis of 7.5±3.8 mm, a mean short-axis of 3.7±0.6 mm, and a mean ratio of the long/short axis of 2±0.3 mm. However, no significant differences among the groups were observed in the long/short axis ratio of the DLN in our study \[[@b10-poljradiol-81-72]\].

According to the generally accepted notion, normal appearing cervical lymph nodes are typically oval in shape. Even cervical lymph nodes enlarged due to a benign inflammatory condition retain their oval shape (long/short axis \>2) \[[@b18-poljradiol-81-72],[@b34-poljradiol-81-72]\]. Albeit statistically insignificant, the DLN long-to-short-axis ratio tended to increase from the control group toward the indeterminate and definite thyroiditis groups (Groups 3 and 4) (mean±standard deviation= 2.0±0.4; 2.2±0.4; 2.4±0.4, and 2.3±0.5 respectively), and the lymph node acquired a more oval configuration ([Table 4](#t4-poljradiol-81-72){ref-type="table"}). This finding corresponds to the pattern observed during long-term inflammatory events. Giovagnorio et al. reported a ratio of 1.7±0.5 in patients with a recent thyroiditis diagnosis and 1.6±0.4 in patients already diagnosed with thyroiditis \[[@b10-poljradiol-81-72]\].

We observed an increasing trend in vascularity with the progress of thyroiditis. Vascularity increased only slightly in the indeterminate group, which was not helpful for the diagnosis. Increased thyroid gland vascularity in response to inflammation and antibody titres was more prominent in Groups 3 and 4 than those in the control and indeterminate groups.

Thyroid gland vascularity tended to increase between the control and intermediate case groups (6.7% and 12.1%, respectively); however, the difference was not significant; therefore, vascularity cannot be used as a marker. There were also noticeable differences among Groups 2, 3, and 4 (12.1, 29.2, and 28.2%, respectively); however, the differences were not significant. Gland vascularity varies in AT cases and is generally associated with the development of hypothyroidism \[[@b29-poljradiol-81-72]\]. This is consistent with our findings showing that increased vascularity was more common in advanced stages of AT (Group 4).

The TPO Ab level is closely associated with cell-mediated cytotoxicity, whereas the Tg Ab is not \[[@b35-poljradiol-81-72]\]. TPO Ab level is representative of current AT activity and associated destruction of the thyroid gland \[[@b36-poljradiol-81-72]\]. TPO Ab levels were significantly correlated with the presence of the DLN and with the DLN measurements (long- and short-axis) ([Table 5](#t5-poljradiol-81-72){ref-type="table"}).

With the progression of AT, increased lymphocytic infiltration eventually causes cell destruction. Moreover, the TPO Ab levels, which are related to cell-mediated cytotoxicity, increase accordingly. As the disease advances, the inflammatory response increases and this causes secondary sonographic changes (shown in [Table 1](#t1-poljradiol-81-72){ref-type="table"}). The increased inflammatory response is mainly responsible for the increase in parenchyma vascularisation and DLN dimensions.

The main limitation of this study was the relatively small number of cases in the series.

Conclusions
===========

A thorough assessment of the Delphian lymph node can give valuable information for the diagnosis of autoimmune thyroiditis. Its importance increases with progression of the disease, and it might help to avoid missing the diagnosis during early stages of the disease when the laboratory results are inconclusive and sonographic results are relatively weak.
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![(**A, B**) Normal sonographic findings in Group 1 (control group).](poljradiol-81-72-g001){#f1-poljradiol-81-72}

![Patients in Group 2 (indeterminate cases) had normal laboratory thyroid hormone levels (**A**) on longitudinal ultrasonography (US); thus, it is difficult to say whether the parenchyma is slightly micronodular or not. No other US features of thyroiditis are seen, and gland vascularity (not shown here) is normal (**B**), Delphian lymph node with a regular contour, oval shape, and hypoechoic is seen above the isthmus but the echogenic hilum cannot be easily seen.](poljradiol-81-72-g002){#f2-poljradiol-81-72}

![Features of the thyroid glands in Group 3 (established thyroiditis), (**A, B**) show increased gland size, slightly irregular contour, and reduced gland echogenicity (**C**), a more prominent Delphian lymph node is shown.](poljradiol-81-72-g003){#f3-poljradiol-81-72}

![Group 4 cases (advanced-late stage thyroiditis). (**A**) Gland size is reduced and an irregular contour is more evident. Gland echogenicity is reduced in a patchy fashion and even in a slightly pseudonodular form. (**B**) Gland vascularity increased minimally and in (**C**), Delphian lymph node is seen clearly.](poljradiol-81-72-g004){#f4-poljradiol-81-72}

###### 

Sonographic features of the groups.

  Sonographic criteria                    Group 1 control cases   Group 2 Early stage/indeterminate cases                                                                                                    Group 3 Established thyroiditis cases                                                                                                                                                                                                                             Group 4 Late stage/advanced thyroiditis cases
  --------------------------------------- ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Volume                                  Normal                  Increased \[[@b19-poljradiol-81-72],[@b20-poljradiol-81-72],[@b21-poljradiol-81-72]\], normal \[[@b15-poljradiol-81-72]\]                  Increased \[[@b19-poljradiol-81-72], [@b21-poljradiol-81-72], [@b22-poljradiol-81-72]\], normal                                                                                                                                                                   Decreased \[[@b21-poljradiol-81-72],[@b23-poljradiol-81-72]\]
  Echotexture                             Homogeneous             Homogeneous \[[@b15-poljradiol-81-72]\], slightly het. \[[@b24-poljradiol-81-72]\]                                                         Heterogeneous \[[@b16-poljradiol-81-72],[@b17-poljradiol-81-72],[@b20-poljradiol-81-72],[@b21-poljradiol-81-72],[@b24-poljradiol-81-72],[@b25-poljradiol-81-72],[@b26-poljradiol-81-72]\]                                                                         Heterogeneous \[[@b17-poljradiol-81-72],[@b21-poljradiol-81-72],[@b22-poljradiol-81-72],[@b23-poljradiol-81-72],[@b25-poljradiol-81-72],[@b26-poljradiol-81-72],[@b27-poljradiol-81-72]\]
  Echogenicity (compare to the muscles)   Hyperechoic             Hyperechoic \[[@b15-poljradiol-81-72],[@b19-poljradiol-81-72]\], slightly hypoechoic \[[@b22-poljradiol-81-72],[@b28-poljradiol-81-72]\]   Hypoechoic \[[@b13-poljradiol-81-72],[@b16-poljradiol-81-72],[@b17-poljradiol-81-72],[@b19-poljradiol-81-72],[@b20-poljradiol-81-72], [@b21-poljradiol-81-72],[@b22-poljradiol-81-72],[@b24-poljradiol-81-72],[@b25-poljradiol-81-72],[@b28-poljradiol-81-72]\]   Hypoechoic \[[@b17-poljradiol-81-72],[@b21-poljradiol-81-72],[@b22-poljradiol-81-72],[@b25-poljradiol-81-72],[@b27-poljradiol-81-72],[@b28-poljradiol-81-72]\]
  Contouring                              Smooth                  Smooth \[[@b15-poljradiol-81-72]\]                                                                                                         Lobulation \[[@b26-poljradiol-81-72]\], smooth                                                                                                                                                                                                                    Irregular \[[@b23-poljradiol-81-72],[@b26-poljradiol-81-72]\]
  Nodulation/ pseudonodulation            No                      No \[[@b15-poljradiol-81-72]\], slightly nodular \[[@b13-poljradiol-81-72],[@b21-poljradiol-81-72]\]                                       Slightly nodular \[[@b13-poljradiol-81-72],[@b21-poljradiol-81-72]\]                                                                                                                                                                                              Pseudonodulation \[[@b17-poljradiol-81-72],[@b21-poljradiol-81-72],[@b25-poljradiol-81-72],[@b27-poljradiol-81-72]\]
  Vascularization                         Normal                  Normal \[[@b15-poljradiol-81-72]\], increased \[[@b29-poljradiol-81-72]\]                                                                  Increased \[[@b21-poljradiol-81-72],[@b29-poljradiol-81-72],[@b30-poljradiol-81-72]\], inormal,                                                                                                                                                                   Increased \[[@b21-poljradiol-81-72],[@b26-poljradiol-81-72],[@b29-poljradiol-81-72]\], normal, decreased \[[@b23-poljradiol-81-72]\]

###### 

Characteristics of the subjects.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                             N             Age                                                                                                              Gender                                                        fT3                 fT4                                                                                                                       TSH                                                                                                                        TG Ab                                                                                                                  TPO Ab
  ------------------------------------------ ------------- ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------- ------------------- ------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------
  1 Control case                             30                                                                                                                             16 F (%53.3)\                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                            14 M (%46.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Min-Max (median)                                                                                                                                                          2.14--3.60 (3)                                                0.92--1.93 (1.18)   0.45--9.59 (1.73)                                                                                                         10.0--58.4 (17)                                                                                                            5.0--63.5 (5.87)                                                                                                       

  Mean ±SD                                   35.60±11.60                                                                                                                    2.99±0.42                                                     1.23±0.25           2.11±1.69                                                                                                                 18.97±10.88                                                                                                                10.8±13.37                                                                                                             

  2 Early stage/indeterminate cases          33                                                                                                                             22 F (%66.7)\                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                            11 M (%33.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Min-Max (median)                                                                                                                                                          1.60--3.89 (3.18)                                             0.0--2.19 (1.24)    0.02--65.0 (1.72)                                                                                                         10.0--42.28 (20.15)                                                                                                        5--238 (7.98)                                                                                                          

  Mean ±SD                                   36.73±11.69                                                                                                                    3.07±0.48                                                     1.17±0.42           4.06±11.3                                                                                                                 22.12±9.11                                                                                                                 23.85±53.05                                                                                                            

  3 Established thyroiditis cases            24                                                                                                                             20 F (%83.3)\                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                            4 M (%16.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Min-Max (median)                                                                                                                                                          2.17--18.66 (2.99)                                            0.84--4.45 (1.04)   0.005--13.65 (5.5)[\*\*](#tfn1-poljradiol-81-72){ref-type="table-fn"},[\#](#tfn2-poljradiol-81-72){ref-type="table-fn"}   14.24--1262.0 (353)[\*\*](#tfn1-poljradiol-81-72){ref-type="table-fn"},[\#](#tfn2-poljradiol-81-72){ref-type="table-fn"}   5--600 (51.45)[\*\*](#tfn1-poljradiol-81-72){ref-type="table-fn"},[\#](#tfn2-poljradiol-81-72){ref-type="table-fn"}    

  Mean ±SD                                   37.96±14.31                                                                                                                    4.78±5.01                                                     1.31±0.85           5.6±4.17                                                                                                                  338.72 ±349.93                                                                                                             209.76 ±235.39                                                                                                         

  4 Late stage/ advanced thyroiditis cases   39                                                                                                                             32 F (%82.1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                            7 M (%17.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Min-Max (median)                                                                                                                                                          2.15--7.58 (2.83)                                             0.30--13 (1.16)     0.005--100 (3.06)                                                                                                         16--1151 (128)                                                                                                             5--2550 (276)                                                                                                          

  Mean ±SD                                   37.87±11.55                                                                                                                    3.22±1.14                                                     1.49±2.02           10.58±23.9                                                                                                                235.39 ±265.89 [\*\*](#tfn1-poljradiol-81-72){ref-type="table-fn"},[\#](#tfn2-poljradiol-81-72){ref-type="table-fn"}       376.24 ±512.11 [\*\*](#tfn1-poljradiol-81-72){ref-type="table-fn"},[\#](#tfn2-poljradiol-81-72){ref-type="table-fn"}   

  *p* Kruskal-Wallis Test                                  [a](#tfn3-poljradiol-81-72){ref-type="table-fn"}***0.001***[\*\*](#tfn1-poljradiol-81-72){ref-type="table-fn"}   [b](#tfn4-poljradiol-81-72){ref-type="table-fn"}***0.031***   ***0.421***         ***0.159***                                                                                                               ***0.001***[\*\*](#tfn1-poljradiol-81-72){ref-type="table-fn"}                                                             ***0.001***[\*\*](#tfn1-poljradiol-81-72){ref-type="table-fn"}                                                         ***0.001***[\*\*](#tfn1-poljradiol-81-72){ref-type="table-fn"}
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

p\<0.01 compared to Control group by using Mann-Whitney U Test;

p\<0.01 compared to Indeterminate group by using Mann-Whitney U Test;

One-way ANOVA Test;

Pearson Chi-Square Test, ^\*\*^ p\<0.01, ^\*^ p\<0.05.

###### 

Assessment of DLNs and gland vascularity according to the groups.

                                Vascularity                                                                                                    Delphian lymph node                                                                                                           
  ----------------------------- -------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ------------ -----------------------------------------------------------------------------------------------------------------
  1 Control                     28 (%93.3)                                                                                                     2 (%6.7)                                                                                                         27 (%90.0)   3 (%10.0)
  2 Early stage/indeterminate   29 (%87.9)                                                                                                     4 (%12.1)                                                                                                        28 (%84.8)   5 (%15.2)
  3 Established thyroiditis     17 (%70.8)                                                                                                     7 (%29.2)                                                                                                        14 (%58.3)   10 (%41.7)[\*](#tfn7-poljradiol-81-72){ref-type="table-fn"}
  4 Advanced thyroiditis        28 (%71.8)                                                                                                     11 (%28.2)[\*](#tfn7-poljradiol-81-72){ref-type="table-fn"}                                                      17 (%43.6)   22 (%56.4)[\*\*](#tfn8-poljradiol-81-72){ref-type="table-fn"},[\#](#tfn9-poljradiol-81-72){ref-type="table-fn"}
  *p*                           [a](#tfn5-poljradiol-81-72){ref-type="table-fn"}***0.028***[\*](#tfn7-poljradiol-81-72){ref-type="table-fn"}   [b](#tfn6-poljradiol-81-72){ref-type="table-fn"}***0.001***[\*\*](#tfn8-poljradiol-81-72){ref-type="table-fn"}                

Fisher-Freeman-Halton Test;

Pearson Chi-SquareTest, ^\*^ p\<0.05, ^\*\*^ p\<0.01.

p\<0.01 compared to Control group by using Mann -Whitney U Test;

p\<0.01 compared to Control group by using Mann-Whitney U Test;

p\<0.01 compared to Indeterminate by using Mann-Whitney U Test.

###### 

Assessment of DLNs according to the groups.

                                                                                                                   Delphian lymph node long axis                                          Delphian lymph node short axis                                  Delphian lymph node long/short ratio
  ----------------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------
  1 Control cases                           N                                                                      3                                                                      3                                                               3
  Min-Max (median)                          2--4.1 (2.7)                                                           1.2--1.8 (1.3)                                                         1.54--2.28 (2.25)                                               
  Mean ±SD                                  2.93±1.07                                                              1.43±0.32                                                              2.02±0.42                                                       
  2 Early stage/indeterminate cases         N                                                                      5                                                                      5                                                               5
  Min-Max (median)                          4.1--10.0 (5.3) [\*](#tfn10-poljradiol-81-72){ref-type="table-fn"}     1.9--4.0 (2.8) [\*](#tfn10-poljradiol-81-72){ref-type="table-fn"}      1.60--2.52 (2.29)                                               
  Mean ±SD                                  6.22±2.26                                                              2.82±0.86                                                              2.21±0.37                                                       
  3 Established thyroiditis cases           N                                                                      10                                                                     10                                                              10
  Min-Max (median)                          3.5--9.6 (5.6) [\*](#tfn10-poljradiol-81-72){ref-type="table-fn"}      1.8--4.0 (2.4) [\*](#tfn10-poljradiol-81-72){ref-type="table-fn"}      1.84--2.91 (2.44)                                               
  Mean ±SD                                  6.06±2.09                                                              2.50±0.71                                                              2.41±0.42                                                       
  4 Late stage/advanced thyroiditis cases   N                                                                      22                                                                     22                                                              22
  Min-Max (median)                          4.1--10.0 (6.6) [\*\*](#tfn11-poljradiol-81-72){ref-type="table-fn"}   1.8--4.4 (3.05) [\*\*](#tfn11-poljradiol-81-72){ref-type="table-fn"}   1.63--3.81 (2.27)                                               
  Mean ±SD                                  6.94±1.65                                                              3.08±0.76                                                              2.31±0.5                                                        
  *p* (Kruskal-Wallis Test)                                                                                        ***0.020***[\*](#tfn10-poljradiol-81-72){ref-type="table-fn"}          ***0.011***[\*](#tfn10-poljradiol-81-72){ref-type="table-fn"}   ***0.483***

p\<0.01 compared to Control group by using Mann-Whitney U Test;

p\<0.01 compared to Control group by using Mann-Whitney U Test.

###### 

Correlations among the DLNs, gland vascularity and Tg Ab and TPO Ab.

                        Tg Ab                   TPO Ab                                                                                                                                                                                                       
  --------------------- ----------------------- ----------------------- ------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
  Delphian lymph node   Long axis               0.246                   ***0.126***                                                                                                        0.521                                                             ***0.001***[\*\*](#tfn15-poljradiol-81-72){ref-type="table-fn"}
  Short axis            0.286                   ***0.073***             0.429                                                                                                              ***0.001***[\*\*](#tfn15-poljradiol-81-72){ref-type="table-fn"}   
  Long/short ratio      −0.032                  ***0.844***             0.078                                                                                                              ***0.614***                                                       
                        **Mean ±SD (median)**   ***p***                 **Mean ±SD (median)**                                                                                              ***p***                                                           
  Vascularity           Normal                  96.66±176.06 (21.8)     [a](#tfn13-poljradiol-81-72){ref-type="table-fn"}***0.013***[\*](#tfn14-poljradiol-81-72){ref-type="table-fn"}     95.65±264.54 (11.9)                                               [a](#tfn13-poljradiol-81-72){ref-type="table-fn"}***0.002***[\*\*](#tfn15-poljradiol-81-72){ref-type="table-fn"}
  Increased             201.61±287.26 (62.1)    231.40±260.91 (135.0)                                                                                                                                                                                        
  Delphian lymph node   Negative                77.63±160.93 (19.8)     [a](#tfn13-poljradiol-81-72){ref-type="table-fn"}***0.001***[\*\*](#tfn15-poljradiol-81-72){ref-type="table-fn"}   51.66±100.66 (10.6)                                               [a](#tfn13-poljradiol-81-72){ref-type="table-fn"}***0.001***[\*\*](#tfn15-poljradiol-81-72){ref-type="table-fn"}
  Positive              201.96±259.74 (60.5)    267.67±423.75 (138.0)                                                                                                                                                                                        

r = Spearman Correlation Coefficient,

Mann-Whitney U Test,

p\<0.05;

p\<0.01.
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